1. Atossa will present at the Jefferies Global Healthcare Conference. 2. Presentation scheduled for June 5, 2025, at 7:35 a.m. ET. 3. The webcast of the presentation will be archived for 30 days. 4. (Z)-endoxifen is Atossa's lead candidate for breast cancer treatment. 5. Atossa focuses on innovative solutions for improving breast cancer outcomes.
Atossa's presentation at a leading healthcare conference can enhance visibility, attracting investor interest, similar to past conference presentations positively impacting stock prices of biotech firms.
The announcement outlines a significant corporate event that showcases Atossa's commitment to its innovative treatment approach, which is crucial for shareholder value.
The upcoming conference presentation could lead to immediate investor excitement and potential short-term movement in ATOS’s stock price.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that Dr. Steven Quay, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 7:35 a.m. Eastern Time.
A live webcast of the presentation can be accessed on the Investors section of the Atossa website under "Events and Presentations" at https://investors.atossatherapeutics.com/news-events/events-presentations. The webcast will be archived for 30 days.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company's lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including prevention, neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com.
SOURCE Atossa Therapeutics Inc